Novelix clearly differentiates itself from most start-up biopharmaceutical companies through:
-
First-in-class targeted small molecule drugs for a broad range of cancer types including skin, lung and colon cancer.
-
Successful human pilot on NVX-207.
-
A business model designed to mitigate risk through alliance-driven drug development.
-
An experienced management and scientific team with a focus on shareholder value.
-
Profitability in our second year of operations based on Novelix’ first licensing deal.
These factors position Novelix as an integrated drug discovery and development company that has the potential to commercialize innovative cancer therapeutics generated in three independent programs through partnerships ultimately positioning the company as an acquisition target. Achieving our corporate milestones will lead to a rich development pipeline optimizing shareholder value. Management’s intention is to provide investors with the option to exit from their investment within a 3-5 year time frame should they so wish.